The significance of HERC5, IFIH1, SAMD4, SEMA3A and MCTP1 genes expression in resistance to cytotoxic drugs in ovarian cancer cell lines

Nowacka, Marta; Ginter-Matuszewska, Barbara; Świerczewska, Monika; Nowicki, Michał; Zabel, Maciej; Sterzyńska, Karolina; Januchowski, Radosław

doi:10.2478/acb-2021-0019

Abstract

Resistance to chemotherapy is the main obstacle in contemporary ovarian cancer treatment. The aim of this study was the evaluation of expression of HERC5, IFIH1, SAMD4, MCTP1 and SEMA3A mRNA and assessment their role in resistance to cisplatin, paclitaxel, doxorubicin and topotecan in seven ovarian cancer cell lines. MTT assay was used in resistance assessment. Quantitative polymerase chain reaction was performed to measure the expression levels of the genes. We observed different levels of resistance among cell lines. The resistance was not related to the expression of drug transporters genes. The expression of HERC5 and IFIH1 genes was upregulated, and the expression of SEMA3A gene was downregulated. Expression of SAMD4 was upregulated in PEA1, PEA2, and PEO23 cell lines, and expression of MCTP1 was downregulated in A2780, PEA2, and PEO23 cell lines. Upregulation of HERC5, IFIH1, and SAMD4 and downregulation of SEMA3A and MCTP1 in TOP-resistant ovarian cancer cell lines may suggest some role of those genes in topotecan resistance development.

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34; DOI:10.3322/caac.21551.
Open DOI Search in Google Scholar Back to article
Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14; DOI:10.1016/j.bpobgyn.2016.08.006.
Open DOI Search in Google Scholar Back to article
Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Annals of Oncology. 2017;28:viii51–6; DOI:10.1093/annonc/mdx441.
Open DOI Search in Google Scholar Back to article
Webber K, Friedlander M. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:126–138; DOI:10.1016/j.bpobgyn.2016.11.004.
Open DOI Search in Google Scholar Back to article
Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478(1–2):23–43; DOI:10.1016/s0027-5107(01)00141-5.
Open DOI Search in Google Scholar Back to article
Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007;63(1):12–31; DOI:10.1016/j.critrevonc.2007.02.001.
Open DOI Search in Google Scholar Back to article
Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998;18(4):259–96; DOI:10.1002/(sici)1098-1128(199807)18:4<259::aid-med3>3.0.co;2-u.
Open DOI Search in Google Scholar Back to article
Januchowski R, Sterzyńska K, Zaorska K, Sosińska P, Klejewski A, Brązert M, Nowicki M, Zabel M. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res. 2016;9(1):65; DOI:10.1186/s13048-016-0278-z.
Open DOI Search in Google Scholar Back to article
Januchowski R, Wojtowicz K, Andrzejewska M, Zabel M. Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines. Biomed Pharmacother. 2014;68(1):111–7; DOI:10.1016/j.biopha.2013.09.004.
Open DOI Search in Google Scholar Back to article
Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26(6):890–6. DOI:10.1200/JCO.2007.13.6606.
Open DOI Search in Google Scholar Back to article
Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger W. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26(19):3176–82; DOI:10.1200/JCO.2007.15.1258.
Open DOI Search in Google Scholar Back to article
Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A. 2002;99(24):15387–92; DOI:10.1073/pnas.242259599.
Open DOI Search in Google Scholar Back to article
Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res. 1999;5(11):3352–6.
Search in Google Scholar Back to article
Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007;26(1):39–57; DOI:10.1007/s10555-007-9042-6.
Open DOI Search in Google Scholar Back to article
Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int. 2013;2013:241763; DOI:10.1155/2013/241763.
Open DOI Search in Google Scholar Back to article
Sterzyńska K, Kaźmierczak D, Klejewski A, Świerczewska M, Wojtowicz K, Nowacka M, Brązert J, Nowicki M, Januchowski R. Expression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines. Int J Mol Sci. 2019;20(16):3927; DOI:10.3390/ijms20163927.
Open DOI Search in Google Scholar Back to article
Sterzyńska K, Klejewski A, Wojtowicz K, Świerczewska M, Nowacka M, Kaźmierczak D, Andrzejewska M, Rusek D, Brązert M, Brązert J, Nowicki M, Januchowski R. Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development. Int J Mol Sci. 2018;20(1):54; DOI:10.3390/ijms20010054.
Open DOI Search in Google Scholar Back to article
Klejewski A, Sterzyńska K, Wojtowicz K, Świerczewska M, Partyka M, Brązert M, Nowicki M, Zabel M, Januchowski R. The significance of lumican expression in ovarian cancer drug-resistant cell lines. Oncotarget. 2017;8(43):74466–74478; DOI:10.18632/oncotarget.20169.
Open DOI Search in Google Scholar Back to article
Sterzyńska K, Klejewski A, Wojtowicz K, Świerczewska M, Andrzejewska M, Rusek D, Sobkowski M, Kędzia W, Brązert J, Nowicki M, Januchowski R. The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines. Int J Mol Sci. 2018;19(10):2901; DOI:10.3390/ijms19102901.
Open DOI Search in Google Scholar Back to article
Świerczewska M, Klejewski A, Wojtowicz K, Brązert M, Iżycki D, Nowicki M, Zabel M, Januchowski R. New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines. Molecules. 2017;22(10):1717; DOI:10.3390/molecules22101717.
Open DOI Search in Google Scholar Back to article
Klejewski A, Świerczewska M, Zaorska K, Brązert M, Nowicki M, Zabel M, Januchowski R. New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines. Anticancer Res. 2017;37(4):1625–1636; DOI:10.21873/anticanres.11493.
Open DOI Search in Google Scholar Back to article
Świerczewska M, Klejewski A, Brązert M, Kaźmierczak D, Iżycki D, Nowicki M, Zabel M, Januchowski R. New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines. Molecules. 2018;23(4):891; DOI:10.3390/molecules23040891.
Open DOI Search in Google Scholar Back to article
Wong JJ, Pung YF, Sze NS, Chin KC. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc Natl Acad Sci U S A. 2006;103(28):10735–40; DOI:10.1073/pnas.0600397103.
Open DOI Search in Google Scholar Back to article
Huang YF, Bulavin DV. Oncogene-mediated regulation of p53 ISGylation and functions. Oncotarget. 2014;5(14):5808–18; DOI:10.18632/oncotarget.2199.
Open DOI Search in Google Scholar Back to article
Kiessling A, Hogrefe C, Erb S, Bobach C, Fuessel S, Wessjohann L, Seliger B. Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene. 2009;28(28):2606–20; DOI:10.1038/onc.2009.115.
Open DOI Search in Google Scholar Back to article
Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441(7089):101–5; DOI:10.1038/nature04734.
Open DOI Search in Google Scholar Back to article
Lin L, Su Z, Lebedeva IV, Gupta P, Boukerche H, Rai T, Barber GN, Dent P, Sarkar D, Fisher PB. Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis. Cell Death Differ. 2006;13(11):1982–93; DOI:10.1038/sj.cdd.4401899.
Open DOI Search in Google Scholar Back to article
Pinder BD, Smibert CA. Smaug: an unexpected journey into the mechanisms of post-transcriptional regulation. Fly (Austin). 2013;7(3):142–5; DOI:10.4161/fly.24336.
Open DOI Search in Google Scholar Back to article
Aviv T, Lin Z, Lau S, Rendl LM, Sicheri F, Smibert CA. The RNA-binding SAM domain of Smaug defines a new family of post-transcriptional regulators. Nat Struct Biol. 2003;10(8):614–21; DOI:10.1038/nsb956.
Open DOI Search in Google Scholar Back to article
Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, Seano G, Serini G, Bussolino F, Giraudo E. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest. 2009;119(11):3356–72; DOI:10.1172/JCI36308.
Open DOI Search in Google Scholar Back to article
Tang C, Gao X, Liu H, Jiang T, Zhai X. Decreased expression of SEMA3A is associated with poor prognosis in gastric carcinoma. Int J Clin Exp Pathol. 2014;7(8):4782–94.
Search in Google Scholar Back to article
Song X, Zhang W, Zhang Y, Zhang H, Fu Z, Ye J, Liu L, Song X, Wu Y. Expression of semaphorin 3A and neuropilin 1 with clinicopathological features and survival in human tongue cancer. Med Oral Patol Oral Cir Bucal. 2012;17(6):e962–8; DOI:10.4317/medoral.18168.
Open DOI Search in Google Scholar Back to article
Jiang H, Qi L, Wang F, Sun Z, Huang Z, Xi Q. Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma. Int J Mol Med. 2015;35(5):1374–80; DOI:10.3892/ijmm.2015.2142.
Open DOI Search in Google Scholar Back to article
Shin OH, Han W, Wang Y, Südhof TC. Evolutionarily conserved multiple C2 domain proteins with two transmembrane regions (MCTPs) and unusual Ca2+ binding properties. J Biol Chem. 2005;280(2):1641–51; DOI:10.1074/jbc.M407305200.
Open DOI Search in Google Scholar Back to article
Qiu L, Yu H, Liang F. Multiple C2 domains transmembrane protein 1 is expressed in CNS neurons and possibly regulates cellular vesicle retrieval and oxidative stress. J Neurochem. 2015;135(3):492–507; DOI:10.1111/jnc.13251.
Open DOI Search in Google Scholar Back to article
Abdel-Rahman WM, Lotsari-Salomaa JE, Kaur S, Niskakoski A, Knuutila S, Järvinen H, Mecklin JP, Peltomäki P. The Role of Chromosomal Instability and Epigenetics in Colorectal Cancers Lacking β-Catenin/TCF Regulated Transcription. Gastroenterol Res Pract. 2016;2016:6089658; DOI:10.1155/2016/6089658.
Open DOI Search in Google Scholar Back to article
Hernandez L, Kim MK, Lyle LT, Bunch KP, House CD, Ning F, Noonan AM, Annunziata CM. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol. 2016;142(2):332–40; DOI:10.1016/j.ygyno.2016.05.028.
Open DOI Search in Google Scholar Back to article
Stukova M, Hall MD, Tsotsoros SD, Madigan JP, Farrell NP, Gottesman MM. Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients. J Inorg Biochem. 2015;149:45–8; DOI:10.1016/j.jinorgbio.2015.05.003.
Open DOI Search in Google Scholar Back to article
Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983;43(11):5379–89.
Search in Google Scholar Back to article
Kiessling A, Hogrefe C, Erb S, Bobach C, Fuessel S, Wessjohann L, Seliger B. Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene. 2009;28(28):2606–20; DOI:10.1038/onc.2009.115.
Open DOI Search in Google Scholar Back to article
Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Eshleman JR, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Brown PO, Goggins M. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 2003;162(4):1151–62; DOI:10.1016/S0002-9440(10)63911-9.
Open DOI Search in Google Scholar Back to article
Desai SD, Reed RE, Burks J, Wood LM, Pullikuth AK, Haas AL, Liu LF, Breslin JW, Meiners S, Sankar S. ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood). 2012;237(1):38–49; DOI:10.1258/ebm.2011.011236.
Open DOI Search in Google Scholar Back to article
Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer. 2006;94(10):1465–71; DOI:10.1038/sj.bjc.6603099.
Open DOI Search in Google Scholar Back to article
Wang Y, Ding Q, Xu T, Li CY, Zhou DD, Zhang L. HZ-6d targeted HERC5 to regulate p53 ISGylation in human hepatocellular carcinoma. Toxicol Appl Pharmacol. 2017;334:180–191; DOI:10.1016/j.taap.2017.09.011.
Open DOI Search in Google Scholar Back to article
Tang J, Yang Q, Cui Q, Zhang D, Kong D, Liao X, Ren J, Gong Y, Wu G. Weighted gene correlation network analysis identifies RSAD2, HERC5, and CCL8 as prognostic candidates for breast cancer. J Cell Physiol. 2020;235(1):394–407; DOI:10.1002/jcp.28980.
Open DOI Search in Google Scholar Back to article
Marín-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P, Mellado B. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther. 2012;11(2):329–39; DOI:10.1158/1535-7163.MCT-11-0289.
Open DOI Search in Google Scholar Back to article
Hou DL, Chen L, Liu B, Song LN, Fang T. Identification of common gene networks responsive to radiotherapy in human cancer cells. Cancer Gene Ther. 2014;21(12):542–8; DOI:10.1038/cgt.2014.62.
Open DOI Search in Google Scholar Back to article
Huang C, Wang Y, Huang JH, Liu W. Sema3A drastically suppresses tumor growth in oral cancer Xenograft model of mice. BMC Pharmacol Toxicol. 2017 Jul 6;18(1):55; DOI:10.1186/s40360-017-0163-4.
Open DOI Search in Google Scholar Back to article
Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008;10:e19; DOI:10.1017/S1462399408000744.
Open DOI Search in Google Scholar Back to article
Świerczewska M, Sterzyńska K, Wojtowicz K, Kaźmierczak D, Iżycki D, Nowicki M, Zabel M, Januchowski R. PTPRK Expression Is Down-regulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations. Int J Mol Sci. 2019;20(8):2053; DOI:10.3390/ijms20082053.
Open DOI Search in Google Scholar Back to article

The significance of HERC5, IFIH1, SAMD4, SEMA3A and MCTP1 genes expression in resistance to cytotoxic drugs in ovarian cancer cell lines

Abstract

Paradigm

My account